-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune heart blood vessels metabolic syndrome research study evidence, -23 / IL-17 immune pathway of interleukin (IL) is a key factor in psoriasis inflammation, evidence suggests that interleukin (IL) -23 / IL-17 immunity Pathway is a key factor in psoriasis inflammation, IL-17A's ixekizumab and seckinumab, IL-17 receptor subunit brodalab, and IL-23's risankizumab, guselkumab, and tildrakizumab IL-17A's ixekizumab and seckinumab, targeting IL -17 receptor subunit brodalab, and risankizumab, guselkumab, and tildrakizumab for IL-23
Neutralizing IL-17A and IL-17F may be more effective than blocking IL-17A alone
Dual inhibition of IL-17A and IL-17F seems to be another effective and safe treatment option for psoriasis
Freitas E, Blauvelt A, Torres T,Bimekizumab for the Treatment of Psoriasis.
Leave a message here